Moderna: Trials and Access

The Moderna COVID-19 vaccine may soon reach young children in the US, but it remains largely elusive in Africa.
 
Quick takes:
 
Not yet peer-reviewed, interim data showed Moderna’s vaccine generated a strong immune response in children ages 6–11 with safety comparable to that seen in adults and adolescents, Reuters reports.  The company said it will soon submit the data to regulators in multiple countries.
 
In a deal partly arranged by the White House and that includes delaying delivery of 33 million doses to the US, the African Union plans to buy up to 110 million doses from Moderna, according to Reuters via U.S. News & World Report. The doses will arrive in batches of 15 million by year’s end, 35 million in 2022’s first quarter and 60 million in the second quarter.
 
2 Biden administration officials told the Washington Post that the US doesn’t have the authority to release details about the Moderna’s vaccine secrets. This despite the fact that the US government has given Moderna nearly $10 billion to run trials and expand its manufacturing. The Biden administration has been under increasing pressure to do more to expand COVID-19 vaccine access to countries in Africa and elsewhere.

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top